The ‘4S’ Pathway was designed to guide shifting needs in older adults with diabetes who are struggling with diabetes ...

“The question is whether or not we can come up with a therapeutic regimen that will reduce their symptoms ... an ACE inhibitor or ARB at the maximally tolerated dose, and low-dose aspirin—or usual ...

There's something about low education level and low ... Misses Endpoint A novel antiplatelet regimen of extended ticagrelor monotherapy with aspirin added just for the first month after stenting ...

An intensive three-drug regimen of heart medications did not ... patients may benefit from heart medications like statins, low-dose aspirin and angiotensin converting enzyme (ACE) inhibitor ...

It is normal for a person who has undergone any cardiac procedure or surgery to be placed on a lifelong daily regimen ... the prescribed dose for analgesia today. Low-dose aspirin was a quarter ...

An intensive three-drug regimen of heart medications did not ... followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients ...

An intensive three-drug regimen of heart medications did not significantly ... have suggested these patients may benefit from heart medications like statins, low-dose aspirin and angiotensin ...

Exclusion criteria included patients (1) who lacked follow-up imaging data or who were uncontactable during follow-up, (2) with missing data on demographics, aneurysm characteristics, antiplatelet ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical data. The latest results show a high starting dose, fast titration model ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...

Aspire Biopharma Holdings, Inc, a developer of a multi-faceted patent-pending drug delivery technology, announced initiation of its phase 1 single-centre clinical study of its lead therapeutic ...

Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.